Philogen SpA (STU:78Q) ROCE % : -27.38% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Philogen SpA's annualized ROCE % for the quarter that ended in Jun. 2024 was -27.38%.

Philogen SpA ROCE % Historical Data

The historical data trend for Philogen SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA ROCE % Chart

Philogen SpA Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

-16.55

-15.31

-3.35

-3.34

92.04

Philogen SpA Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial					-12.83	17.01	-24.14	-27.38	299.62

Philogen SpA ROCE % Calculation

Philogen SpA's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.699	/	( ( (125.827 - 10.785)	+	(119.27 - 12.71) )	/ 2 )
	=	-3.699	/	( (115.042	+	106.56)	/ 2 )
	=	-3.699	/	110.801
	=	-3.34 %

Philogen SpA's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-26.952	/	( ( (119.27 - 12.71)	+	(104.775 - 14.432) )	/ 2 )
	=	-26.952	/	( ( 106.56	+	90.343 )	/ 2 )
	=	-26.952	/	98.4515
	=	-27.38 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Philogen SpA (STU:78Q) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Philogen SpA ROCE % Related Terms

Thank you for viewing the detailed overview of Philogen SpA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Philogen SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (STU:78Q) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PHIL:Italy

Address

Piazza La Lizza No. 7, Siena, ITA, 53100

Website

https://www.philogen.com

Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Philogen SpA Headlines

No Headlines